The publicly listed company Prenetics will obtain more funds by selling its subsidiary ACT Genomics to explore Bitcoin reserve strategies.

robot
Abstract generation in progress

PANews June 18 news, according to an official announcement, consumer health science company Prenetics (NASDAQ: PRE) has reached a final agreement to transfer its ownership of genomic medicine business ACT Genomics Holdings to Delta Electronics (TWSE: 2308). The total transaction value is up to $71.78 million, and Prenetics expects to receive approximately $46 million in cash. After the transaction is completed, the company’s cash reserves will increase to $86 million, with short-term assets reaching $117 million, while maintaining a zero-debt status. CEO Danny Yeung stated that the ample cash reserves will enable the company to explore innovative financial strategies such as digital asset and Bitcoin treasury management.

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Share
Comment
0/400
No comments
Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate app
Community
English
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)